Interim report 1 january - 30 september 1999

INTERIM REPORT 1 JANUARY - 30 SEPTEMBER 1999 Proof of principle has been achieved in the development of new treatments for obesity and high cholesterol. This triggers the first milestone payment in the collaboration with Bristol-Myers Squibb. Clinical indications have been prioritized in the Merck collaboration. The project has been up-graded by Merck. Patents on the estrogen receptor beta have been granted in Europe and in the U.S. Animal trials with new compound classes strengthen Karo Bio's diabetes project. Net sales for the period amounted to SEK 46.0 million (46.6) Net result after financial items for the period amounted to SEK -32.2 million (-15.7). Liquid funds and short-term investments as of 30 September amounted to SEK 182.3 million, compared with SEK 209.1 million as of 31 December 1998. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/10/18/19991104BIT01000/bit0001.doc http://www.bit.se/bitonline/1999/10/18/19991104BIT01000/bit0002.pdf http://www.bit.se/bitonline/1999/10/18/19991104BIT01000/bit0003.xls Tabels